Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab and Cobolimab in Advanced Cervical Cancer
NCT06238635Phase 2Active, not recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of dostarlimab and cobolimab in Cervical Cancer (CC) (2 cohorts). Primary endpoint: Objective Response Rate Based on irRECIST up to 2 years. Started Mar 2024; status: active, not recruiting.
02
Drugs
dostarlimabcobolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06238635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238635.